Literature DB >> 12821662

Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells.

Sean R Conner1, Glynis Scott, Andrew E Aplin.   

Abstract

Normal cells are dependent upon integrin-mediated adhesion to the extracellular matrix for cell proliferation and survival. Integrins regulate these processes partially through control of extracellular signal-regulated kinases 1 and 2 (ERK1/2). A trait of malignant cells is their ability to undergo anchorage-independent growth. Melanomas are tumors arising from normal melanocytes that, if undetected at an early stage, are highly invasive and poorly treatable. Proliferation of melanoma cells and melanocytes is dependent upon ERK1/2 signaling, and mutation of B-Raf, a component of the ERK1/2 pathway, is commonly found in melanomas. We addressed the role of integrin-mediated adhesion in ERK1/2 signaling in human melanoma cells and primary melanocytes. Basal ERK1/2 activity was low, and growth factor activation was adhesion-dependent in normal human melanocytes. By contrast in mutant B-Raf-expressing melanoma cells (SK-MEL-24 and SK-MEL-28), the ERK1/2 pathway was constitutively active, and adhesion-dependent regulation of ERK1/2 activity was by-passed. Furthermore, in melanoma cells, ERK1/2 translocated to the nucleus and regulated transcription events in an adhesion-independent manner. Expression of mutant V599E B-Raf in normal melanocytes was sufficient to promote adhesion-independent ERK1/2 signaling. These results indicate that alterations in the adhesion requirement for ERK1/2 signaling in melanocytes are associated with the acquisition of malignant cell behavior.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821662     DOI: 10.1074/jbc.M305797200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

Review 3.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

4.  FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.

Authors:  Michele B Weiss; Ethan V Abel; Neda Dadpey; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-07-24       Impact factor: 5.852

5.  Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.

Authors:  Laurie S Spofford; Ethan V Abel; Karen Boisvert-Adamo; Andrew E Aplin
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

6.  In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Authors:  Ileine M Sanchez; Timothy J Purwin; Inna Chervoneva; Dan A Erkes; Mai Q Nguyen; Michael A Davies; Katherine L Nathanson; Kristel Kemper; Daniel S Peeper; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2019-07-03       Impact factor: 6.261

7.  Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Authors:  Edward J Hartsough; Kevin J Basile; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-02-11       Impact factor: 5.852

8.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.

Authors:  Kaitlyn Le; Erik S Blomain; Ulrich Rodeck; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-08       Impact factor: 4.693

9.  Mcl-1 is required for melanoma cell resistance to anoikis.

Authors:  Karen Boisvert-Adamo; Whitney Longmate; Ethan V Abel; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

10.  alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.

Authors:  Rong Hu; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2010-01-07       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.